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Abstract
The demonstration of bioequivalence (BE) is an essential requirement for ensuring that patients receive a
product that performs as indicated by the label. The BE standard for a particular product is set by its innovator,
and this standard must subsequently be matched by generic drug products. The Biopharmaceutics
Classification System (BCS) sets a scientific basis for an improved BE standard for immediate-release solid
oral dosage forms. In this paper, we discuss BE and the BCS, as well as the issues that are currently relevant to
BE as a pharmaceutical product standard.
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The demonstration of bioequivalence (BE) is an essential 
requirement for ensuring that patients receive a product 
that performs as indicated by the label. The BE standard for 
a particular product is set by its innovator, and this standard 
must subsequently be matched by generic drug products. The 
Biopharmaceutics Classification System (BCS) sets a scientific 
basis for an improved BE standard for immediate-release 
solid oral dosage forms. In this paper, we discuss BE and the 
BCS, as well as the issues that are currently relevant to BE as a 
pharmaceutical product standard.
A recent report by Benet and Larregieu1 in this journal articu-
lates issues, of both science and public policy, that currently 
surround the regulatory BE standard. That report1 focuses on 
the use of study results from metabolism, mass balance, and 
permeability studies and the BCS2,3 to set a BE standard for solid 
oral immediate-release dosage forms, i.e., the use of “biowaiver” 
applications that allow the waiver of an in vivo BE test. Here 
we discuss further issues pertaining to scientific evidence and 
regulatory requirements in BE testing.1
Be TesTing PasT and PresenT
BE, defined by the US Food and Drug Administration’s (FDA’s) 
Orange Book4 as the “display [of] comparable bioavailability 
when studied under similar experimental conditions,” serves 
as a central scientific and regulatory standard for virtually all 
oral pharmaceutical products.5 The most recent regulatory state-
ment on BE, the European Medicines Agency’s “Guideline on 
the Investigation of Bioequivalence” (2010), defines the term 
similarly.6 The Orange Book further follows the language of 
the Drug Price Competition and Patent Term Restoration Act 
(Hatch–Waxman Act) of 1984: “Bioequivalent drug products 
are therapeutically equivalent and, therefore, interchange-
able.”4 Historically the in vivo matching of human systemic 
concentrations of active drug—and, when important for thera-
peutic efficacy, metabolite(s)—and comparison with a reference 
product (e.g., the Reference Listed Drug (product)4) has been 
the gold standard for BE and therapeutic interchangeability. This 
standard is widely accepted. However, the scientific question 
involved here is still open: what evidence should be required to 
support regulatory standards and decisions regarding BE?
develoPmenT of The Be sTandard
The science underlying BE has been much discussed by the phar-
maceutical industry, academics, and regulatory scientists since 
the 1960s. In the 1960s, Congress explored the idea of mandating, 
whenever possible, the prescribing of generic “drugs” (drug prod-
ucts).7 We note that the term “drug” appears frequently in these 
debates; in our opinion, the term is often ambiguous. In almost all 
contexts related to generic equivalence and BE testing, we interpret 
the term “drug” to be a reference to a drug product (as opposed to 
an “active pharmaceutical ingredient”). In regulatory and legisla-
tive language, this ambiguity reaches back as far as Section 6 of 
the Pure Food and Drug Act of 1906, which defines “drug” as “any 
substance or mixture of substances intended to be used for the 
cure, mitigation, or prevention of disease of either man or other 
animals.” We believe that this conflation of the terms “drug” and 
“drug product” impedes our understanding even today.
Although Congress never implemented this generic substitution 
policy idea, BE rapidly revealed itself as a crucial scientific link 
between the extensive clinical efficacy testing required of innova-
tor drug products (i.e., phase III testing) by the 1962 federal drug 
amendments and the marketed forms of those innovator products.8 
The significance of BE in the development of innovator products 
and potential generic equivalents (i.e., therapeutically equivalent 
and interchangeable drug products) also quickly became clear.
Major scientific figures at the time recognized the significance of 
BE testing, if not the complexity of setting a regulatory standard. 
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The pharmacologist Alfred Gilman, for example, wrote the “White 
Paper on the Therapeutic Equivalence of Generic Drugs” in 1969 
for the Policy Advisory Committee of the National Academy of 
Sciences’ Drug Efficacy Study.9,10 Gilman strongly stated that in 
vivo studies were necessary for the demonstration of equivalence. 
He argued that “all producers, and certainly the generic houses, 
should be required to submit proof of the performance of their 
drugs [presumably meaning drug products] in human patients 
before they are permitted to market them.”10 Further investiga-
tion of BE led to a 1974 Office of Technology Assessment report, 
“Drug Bioequivalence,” 8 that presented 11 conclusions and rec-
ommendations to Congress. Although the title of this influential 
report uses the term “Drug,” the report focuses almost exclusively 
on drug products. The initial preliminary publication of a list of 
therapeutically equivalent drug products in the Federal Register 
in 1979 (the list became the first edition of the FDA Orange Book 
one year later (for the current edition, see ref. 4)), represents the 
first binding form of regulatory language based on BE research 
and testing. In the 1980s, after the Drug Price Competition and 
Patent Term Restoration Act of 1984 allowed generic drug firms 
to reference the data contained in innovator companies’ new 
drug applications at the FDA, and allowed generic products to be 
marketed under essentially the same product label as the related 
innovator product, the political and business issues surrounding 
BE—and therefore the need for further scientific development of 
BE testing—became yet more acute.
Both the science and the regulatory policy with respect to BE 
have advanced significantly in the past 25 years.5,11 The value of 
the contribution made by the evolving science and practice of 
in vivo BE studies to ensuring the quality and performance of 
pharmaceutical products is unquestionable. The development 
of BCS-based science and regulation since the early 1990s has 
been another important element in this recent advancement of 
the understanding and implementation of BE.12 Further elabora-
tions of BCS and the development of the Biopharmaceutics and 
Drug Disposition Classification System continue to expand the 
scientific and mechanistic understanding of BE,13,14 as well as 
molecular absorption, distribution, metabolism, and elimina-
tion. Although the relative bioavailability–based view of BE has 
received a substantial amount of scientific consideration since the 
1970s (including study design, population sampling, and statistical 
evaluation11), BE remains a debated and inadequately developed 
approach to regulating pharmaceutical drug products. In particu-
lar, for oral products, the complex relationships between drug 
and drug product dissolution in vivo and the effects of excipients, 
intestinal permeation and transit, absorption, metabolism, excre-
tion, and systemic availability continue to be much discussed. All 
these issues are important to the ongoing development of BE test-
ing, both in vivo and in vitro. BE pertains to the same drug (“active 
pharmaceutical ingredient”) in different products. Dissolution 
testing is currently central to in vitro BE testing, yet major scien-
tific questions remain to be resolved: the feasibility of (i) using  in 
vitro dissolution results to predict in vivo performance and (ii) 
using other data (e.g., absorption, metabolism, and, especially, 
tissue culture results) as a basis for setting in vitro dissolution and 
BE standards. Regulatory standards and practices for BE testing, 
particularly the BCS approach, have highlighted the relationships 
among permeability, absorption, metabolism, and drug dissolu-
tion of the product, in vitro and in vivo, and have established a sci-
entific basis for setting regulatory in vitro BE dissolution standards 
for oral immediate-release products.2,5
The science and PracTice of Be
BE is an essential drug product standard for both innovator and 
generic products. For innovator products, BE is used to establish 
therapeutic equivalence between the commercialized, marketed 
product and the clinical-scale product that underwent phase III 
safety and efficacy testing. The pivotal phase III studies that estab-
lish the evidence for the label indication(s), use(s), and dosing 
require that the clinically tested phase III product show evidence 
of bioavailability. All subsequent products that contain the same 
“drug,” or “active pharmaceutical ingredient,” and label must be 
bioequivalent to that clinically tested product. For example, addi-
tional BE evidence on the innovator product is required when 
the product undergoes various scale-up or postapproval changes 
(see, e.g., FDA SUPAC guidances15). Therefore, BE is the essential 
continuing standard for ensuring the therapeutic interchange-
ability and efficacy of pharmaceutical products.
However, the question of what scientific evidence is necessary 
to ensure BE is still much discussed. The in vivo BE approach has 
limits in its applicability; for example, in vivo studies in healthy 
subjects are difficult to justify when product changes can be con-
sidered “minor” (e.g., changes in color) or a drug has significant 
adverse effects (e.g., cancer and immune therapeutics). The 2010 
European Medicines Agency BE guideline highlights this issue in 
its discussion of the “BCS-Based Biowaiver.”6 BCS has provided 
a sound scientific basis for deciding when in vivo tests should be 
required and when in vitro tests are sufficient or superior to in 
vivo testing for BE. The BCS approach has established that, on 
the basis of current scientific understanding of the dissolution 
and gastrointestinal processes that oral drug products undergo, 
in vivo tests should not be required for certain drugs with cer-
tain drug product characteristics (e.g., high-permeability, high-
solubility drugs in products that dissolve rapidly).2 Current FDA 
practice related to BCS biowaivers is limited to class I (high-per-
meability, high-solubility) drug substances. The 2010 European 
Medicines Agency Bioequivalence Guideline6 further extends 
its discussion of biowaivers to class III (low-permeability, high-
solubility drugs) as well. In both cases, it is essential that the 
product demonstrate certain in vitro dissolution characteristics, 
i.e., rapid or very rapid dissolution.6 For drug products with the 
aforementioned permeability and solubility characteristics, we 
believe that a scientifically sound dissolution test in fact provides 
superior evidence of BE because, in in vivo testing, variations in 
systemic drug levels reflect mainly gastric and intestinal transit 
variations, obscuring product differences.3
PermeaBiliTy, meTaBolism, and aBsorPTion
Benet and Larregieu1 are particularly concerned with the reg-
ulatory use of the term “high permeability”: “We believe that 
using extent of absorption (a thermodynamic measure) and 
intestinal permeability (a kinetic measure) interchangeably is 
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not scientifically sound and is ambiguous from a regulatory per-
spective.” In addition, they write, “An alternative surrogate for 
a high extent of absorption could be a high extent of metabo-
lism” (high fraction metabolized (Fmet)). On the second point 
we agree, because for a drug to be metabolized it must (usually) 
be absorbed (although some 30 drugs have been shown to be 
metabolized by bacterial enzymes in the intestine).16 As for the 
first point, it is clear that Amidon et al. (1995)3 and the 2000 FDA 
BCS guidance2 use the fraction dose absorbed in humans (Fabs) 
as the primary measure of intestinal permeability (of the entire 
gastrointestinal tract). This follows from mass balance analysis, in 
which the extent of absorption is assumed to be the drug lost from 
the intestine (assuming no chemical or enzymatic degradation in 
the gastrointestinal tract) by absorption into the body across the 
(mainly) epithelial cell membrane surface of the gastrointestinal 
tract. We define oral absorption as transport of the drug into the 
“first” biological tissue (the mucosal cells or other cells lining the 
GI tract or passing the tight junctions into the interstitial fluid). 
Systemic availability is often reduced by metabolism in the intes-
tinal and liver tissue (after absorption), i.e., first-pass metabolism. 
The permeability of the whole gastrointestinal tract is, in general, 
dependent on the location in the tract and the time elapsed, given 
cellular differentiation along the gastrointestinal tract, upregula-
tion and downregulation of cellular and membrane components, 
and the changing luminal environment. Experiments with Caco-2 
cell monolayers cannot reflect this in vivo complexity.
The use of the terms “kinetic” and “thermodynamic” to 
describe measures for permeability and extent of absorption 
also needs to be clarified. Permeability is measured as a velocity 
(units cm/s) on the order of 1 × 10−4 cm/s (ref. 17) for a typi-
cal oral drug in the human jejunum. Extent of absorption (like 
extent of reaction) is a measure of absorption (conversion to 
product) in a definite time period (gastrointestinal transit time). 
It is not a thermodynamic value, because the in vivo state is 
clearly not one of equilibrium. The use of the term “high perme-
ability” in this regulatory context is therefore defined by Fabs in 
the context of the FDA guidance,2 although it is not specifically 
stated as a definition in the guidance. The guidance also suggests 
alternative methods for determining high permeability that do 
not require experiments in humans (e.g., using animal or tissue 
culture instead) when scientifically validated.
Benet and Larregieu refer explicitly to permeability as meas-
ured in the commonly used Caco-2 in vitro cell monolayer system. 
Although this system can be used for many mechanistic studies of 
epithelial cell transport processes, it clearly does not represent the 
full range of differentiation of the epithelial cells, other cell types, 
and mucin that line the entire gastrointestinal tract. Although the 
variability of permeability determined in tissue culture18 under var-
ying experimental conditions requires careful consideration,19,20 
published results to date14,18,21 support the use of cell monolayer 
results for determining high permeability (no known false-posi-
tives). The FDA BCS guidance2 clearly states that the suitability 
of a permeability-assessment method must be demonstrated2 
when using the method for BCS classification. The use of results 
pertaining to Caco-2 (or other) cell monolayers, along with other 
supporting results such as pharmacokinetic, physicochemical, and 
estimation methods in human subjects,22 will support a biowaiver 
application. Clearly, given the in vivo complexity, the terms “(intes-
tinal) permeability” and “high permeability” must be used care-
fully and in the appropriate scientific context.23
Studies of Fabs and Fmet in humans vary in complexity depend-
ing on the metabolic and excretion pathways of the particular 
drug and its metabolites.16,24 The 2000 FDA BCS guidance uses 
Fabs in humans as the principal basis for classifying a drug as 
having “high permeability.” The guidance does offer alternative 
approaches to the determination of high permeability. These 
approaches can be used to classify a drug or drug product and 
would require additional information on the drug or drug prod-
uct. Tissue culture results—for example, from the Caco-2 or other 
tissue culture systems—might not be sufficient in themselves to 
enable classification of a drug for regulatory or other purposes 
unless high permeability is suitably demonstrated. Where suffi-
cient information from multiple sources is available (e.g., human 
pharmacokinetic and mass balance data), however, further human 
studies become unnecessary for establishing BE, and additional 
human studies do not add any useful scientific information.
We therefore argue that both Fabs and Fmet should be used as 
evidence on which to determine whether a drug or drug product 
should be classified as having “high permeability.” It is impor-
tant to understand how Fabs and Fmet together provide the data 
necessary to classify a drug for BCS purposes, set a regulatory 
standard, and ensure that BE is based on an adequate range of 
evidence, including dissolution tests. Although it is true that 
considerable metabolism data on drugs are available, these data 
usually focus on metabolite and metabolism pathway identifica-
tion. The data are usually semiquantitative and allow for only 
limited statistical analysis (small numbers of subjects). For 
example, Roffey et al. report, based on a survey, that the mean 
recovery of drug from mass balance studies in humans is 80% 
on average.24 When total dose can actually be accounted for, 
the fraction metabolized, along with other relevant data, can 
be used to classify a drug. However, it is important to note that, 
with the exception of gastrointestinal luminal and brush-border 
instability or metabolism, a drug must be absorbed in order 
to be metabolized. In the case of radiolabel studies involving 
both IV and oral dosing, both Fmet and Fabs can be determined 
(although usually with limited statistical evaluation). In the case 
of data from oral administration alone, however, the metabolites 
need to be identified6,16 before Fmet and Fabs can be determined. 
These complexities in the determination of drug metabolism 
demonstrate that absorption and metabolism should, where 
possible, be investigated and considered together. This would 
ensure greater reliability with regard to drug classification as a 
basis for setting regulatory standards for BE determination.
PuBlic Policy
Benet and Larregieu raise an additional public policy question 
regarding the confidentiality of biowaiver information. We 
acknowledge that these issues often form an undercurrent in the 
debates on BE. The regulatory policy regarding industry prod-
uct proprietary information, market exclusivity, and the open 
availability of regulatory information and related decisions has 
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significant implications for the costs of health care. BE policy also 
has substantial implications for the pharmaceutical industry and 
for the commercial development of new chemical entities. Our 
scientific view of this issue is that a scientifically sound BE disso-
lution test, developed and set on the basis of the clinically tested 
phase III product, would serve as the fundamental BE standard 
for all subsequent products that are pharmaceutically identical4 
to the clinically tested product. We further agree with Benet and 
Larregieu1 that this dissolution test should be made publicly 
available. However, we believe that it should be made publicly 
available only after regulatory approval and the expiration of 
the appropriate patent term and exclusivity periods. The term of 
exclusivity and of confidentiality of this proprietary BE dissolu-
tion methodology needs further discussion. However, this test 
could be developed on a new chemical entity product at the last 
stages of drug development, after attrition of the many unsuccess-
ful drug candidates. Alternatively, it could be developed by regu-
latory authorities (e.g., by the FDA, the US Pharmacopeia, or the 
European Pharmacopoeia) while the innovator drug product is 
being marketed and under exclusivity, and it could then be made 
public after the patent and market exclusivity periods expire. This 
would allow the setting of scientific standards that would ensure 
the continued long-term clinical performance of a drug product 
and reduce the need for expensive and complex testing in human 
subjects. We stress that our view is that a scientifically sound 
BE dissolution test could be more routinely applied to oral drug 
products to ensure performance when certain clearly defined 
(e.g., ref. 15) changes to a drug product are to be made or when 
commercial development or manufacturing requires changes 
outside approved specifications (e.g., unavailability of an excipi-
ent). This BE dissolution test would be applicable worldwide for 
establishing the continued efficacy of this oral drug product.
conclusion
BCS, with its focus on solubility, permeability, and absorption, 
provides a scientific basis for setting strong BE standards for 
oral drug products. Biopharmaceutics and Drug Disposition 
Classification System and metabolic data based on human stud-
ies are also useful to the BE regulatory decision process. Both 
types of information are included in a new drug application and 
may or may not be published and publicly available. The Fmet 
value, when used with a clear understanding of the significant 
metabolic pathways, can be considered being equivalent to the 
Fabs value. Advances in the science of BE have revealed that both 
in vitro and in vivo data are significant in the setting of a scien-
tifically sound BE regulatory policy and standard. Although in 
vivo studies in humans are extensively used to document BE, 
they should no longer be viewed as the only type of evidence that 
can be used to establish the BE of oral drug products.
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